Revakinagene taroretcel
Source Revakinagene taroretcel at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Revakinagene taroretcel (Encelto™, NT‑501) is an encapsulated cell‑based gene therapy that delivers recombinant human ciliary neurotrophic factor (CNTF) directly into the eye. It is approved in the United States for the treatment of adults with idiopathic macular telangiectasia type 2 and is being investigated for other chronic retinal degenerations.
Mechanism of Action
The device contains 200,000‑440,000 allogeneic retinal pigment epithelial cells engineered to secrete recombinant CNTF. CNTF binds to a heterotrimeric receptor complex (CNTFRα, LIFRβ, gp130) on photoreceptors and Müller cells, activating JAK/STAT and PI3K pathways that promote neuronal survival, reduce apoptosis, and modulate inflammation, thereby slowing photoreceptor loss.
What the Research Shows
A retrospective analysis of 49 explanted devices showed steady release of bioactive CNTF at a mean 1.6 ng/day for up to 14.5 years, with no detectable immune reaction. Two phase 3, sham‑controlled trials (NTMT‑03‑A and B) demonstrated a statistically significant reduction in ellipsoid‑zone area loss over 24 months (differences of –0.091 and –0.049 mm², respectively). A review of emerging retinal delivery platforms highlighted revakinagene taroretcel as a pioneering sustained‑release cell therapy, and a 2025 approval article confirmed its first FDA approval for macular telangiectasia type 2. Together, the data support durable intra‑ocular CNTF delivery with measurable anatomical benefit in MacTel.
Reported Benefits
The therapy provides continuous intra‑ocular CNTF from a single implantation, eliminating the need for frequent intravitreal injections. Long‑term analyses show sustained, bioactive release for more than a decade, and phase 3 trials report a meaningful slowing of photoreceptor (ellipsoid‑zone) loss compared with sham. The device did not provoke systemic antibodies to CNTF or the encapsulated cells, indicating low immunogenicity.
Limitations of the Evidence
Efficacy has been demonstrated only in macular telangiectasia type 2; data for other retinal diseases remain limited. Secondary functional outcomes such as retinal sensitivity, reading speed, and visual‑function questionnaires showed inconsistent differences. Adverse ocular effects (miosis, delayed dark adaptation) occurred in a minority of participants. Long‑term safety beyond 15 years and comparative effectiveness versus newer delivery platforms have not been established.
Safety Considerations
Serious adverse events occurred at similar rates to sham procedures. The most common treatment‑related ocular events were miosis (14‑17% of treated eyes) and delayed dark adaptation (17‑24%). No systemic immune response to CNTF or the encapsulated cells was detected, and loss of ≥15 letters in best‑corrected visual acuity did not differ from control groups. Overall safety profile appears acceptable for intra‑ocular implantation, but clinicians should monitor for pupil constriction and dark‑adaptation changes.
How It Is Administered
Revakinagene taroretcel is delivered as a single, surgically placed intravitreal implant containing encapsulated, CNTF‑producing cells. The device remains in the vitreous cavity and continuously releases CNTF over years, eliminating the need for repeat injections. Formulation is a sterile, sealed capsule designed for long‑term biocompatibility.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleModerateKauper K, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleLowRaming K, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateRowe LW, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateHoy SM2025-01-01T00:00:00.000000Z
- Journal ArticleModerateFedotcheva TA, Shimanovsky NL2025-01-01T00:00:00.000000Z
- Journal ArticleModerateChew EY, et al.2025-01-01T00:00:00.000000Z
Frequently Asked Questions
How does revakinagene taroretcel differ from standard intravitreal injections?
Instead of repeated injections of a drug, the therapy uses a surgically implanted capsule that continuously secretes CNTF for years, reducing treatment burden and providing steady drug exposure.
What retinal condition is revakinagene taroretcel currently approved to treat?
It received FDA approval in March 2025 for idiopathic macular telangiectasia type 2 in adults.
What are the most common side effects patients may experience?
Mild pupil constriction (miosis) and delayed dark adaptation have been reported in roughly one‑third of treated eyes; serious adverse events are comparable to sham procedures.
Can the device be removed or replaced if needed?
The capsule is designed for long‑term implantation; removal or replacement would require additional intra‑ocular surgery, which is not routinely performed.
Is revakinagene taroretcel being studied for other eye diseases?
Pre‑clinical and early clinical programs are exploring its use in other chronic retinal degenerations such as retinitis pigmentosa and dry age‑related macular degeneration, but efficacy data are not yet available.
What is Revakinagene taroretcel?
Revakinagene taroretcel (Encelto™, NT‑501) is an encapsulated cell‑based gene therapy that delivers recombinant human ciliary neurotrophic factor (CNTF) directly into the eye. It is approved in the United States for the treatment of adults with idiopathic macular telangiectasia type 2 and is being investigated for other chronic retinal degenerations.